Study summary · research use only
[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study compared functional genome indicators in lymphocyte cultures from patients with hypertrophic cardiomyopathy (HCM) and their first-degree relatives, in intact cultures and cultures exposed to the peptide bioregulators Epithalon, Vilon, and Livagen (Livagen also tested with cobalt chloride salt). The abstract reports that cells from individuals with HCM and their relatives showed higher frequencies of spontaneous quantitative-structural disorders than cells of healthy individuals, and that the bioregulators had differing effects. The authors describe Epithalon as showing the most marked protective normalization of genome parameters and lowering chromosomal instability, and suggest prospects for its use in preventive measures.
Abstract
In this paper, a comparative study of the functional genome indicators using lymphocyte cultures of patients with hypertrophic cardiomyopathy (HCM) and their first relatives. Studies conducted both in intact cultures and cultures exposed to the influence of peptide - bioregulators Epithalon, Vilon and Livagen. Last (Livagen) tested at separate and joint application with cobalt chloride salt. As indicated according to the results of the analysis, the cells of the individuals with HCM and their first relatives were characterized by higher frequency of spontaneous quantitative - structural disorders in comparison with the cells of healthy individuals. The findings suggest a different effect of bioregulators. The most effective protective action in relation normalization of functional parameters of the genome shows Epithalon for lowering the level of chromosomal instability in patients with hypertrophic cardiomyopathy and relatives of patients with HCM. On the basis of identified protective action Epithalon concludes prospects of its application in the development of preventive measures for individuals at increased risk of morbidity HCM.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.